Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Corporate News: Hardman & Co Research (EQS) +++ CHESNARA Aktie +4,67%

KYOWA KIRIN Aktie

 >KYOWA KIRIN Aktienkurs 
14.6 EUR    (Tradegate)
Ask: 14.8 EUR / 338 Stück
Bid: 14.4 EUR / 348 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 8 bis 22 Uhr!
KYOWA KIRIN Aktie über LYNX handeln
>KYOWA KIRIN Performance
1 Woche: +1,0%
1 Monat: -1,7%
3 Monate: +15,0%
6 Monate: +2,1%
1 Jahr: -14,1%
laufendes Jahr: +0,7%
>KYOWA KIRIN Aktie
Name:  KYOWA KIRIN CO. LTD.
Land:  Japan
Sektor:  Gesundheit
ISIN/ Wkn:  JP3256000005 / 858523
Symbol/ Ticker:  KY4 (Frankfurt)
Kürzel:  FRA:KY4, ETR:KY4, KY4:GR
Index:  Nikkei225
Webseite:  https://www.kyowakirin.co..
Marktkapitalisierung:  7840 Mio. EUR
Umsatz:  427098.22 Mio. EUR
EBITDA:  95121.75 Mio. EUR
Gewinn je Aktie:  0.509 EUR
Schulden:  19416.3 Mio. EUR
Liquide Mittel:  185072.15 Mio. EUR
Umsatz-/ Gewinnwachstum:  - / -
KGV/ KGV lG:  25.2 / -
KUV/ KBV/ PEG:  2.62 / 1.55 / -
Gewinnm./ Eigenkapitalr.:  10.39% / -
Dividende je Aktie:  0.345 EUR
Dividendenrendite/ -schätzung:  2.3% / 2.55%
Div. Historie:  27.12.24 - 0.17603€
27.06.24 - 0.16878€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  KYOWA KIRIN
Letzte Datenerhebung:  08.07.25
>KYOWA KIRIN Eigentümer
Aktien: 523.37 Mio. St.
f.h. Aktien: 229.05 Mio. St.
Insider Eigner: 55.01%
Instit. Eigner: 18.81%
Leerverk. Aktien: -
>KYOWA KIRIN Peer Group

 
26.06.25 - 23:42
 XFRA: DIVIDEND/INTEREST INFORMATION - 27.06.2025 - EQUBF_01 (XETRA)
 
Das Instrument KY4 JP3256000005 KYOWA KIRIN CO. LTD. EQUITY wird ex Dividende/Zinsen gehandelt am 27.06.2025 The instrument KY4 JP3256000005 KYOWA KIRIN CO. LTD. EQUITY has its ex-dividend/interest day on 27.06.2025...
12.06.25 - 13:33
 Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress (GlobeNewswire EN)
 
– Encouraging clinical activity with deep responses demonstrated in the KOMET-007 trial with the combination of 600 mg ziftomenib with 7+3 in newly diagnosed patients with NPM1-m and KMT2A-r AML –...
03.06.25 - 00:03
 Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting (GlobeNewswire EN)
 
– CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R NPM1-m AML patients –...
22.05.25 - 23:33
 Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting (GlobeNewswire EN)
 
– Results from KOMET-001 registration-directed trial of ziftomenib in R/R NPM1-m AML patients selected for oral presentation on Monday, June 2nd –...
14.05.25 - 16:03
 Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress (GlobeNewswire EN)
 
– Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r AML patients selected for oral presentation on Thursday, June 12th –...
08.04.25 - 13:33
 Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA (GlobeNewswire EN)
 
– Submission seeks approval for the treatment of adult patients with relapsed or refractory AML with a NPM1 mutation – – Submission seeks approval for the treatment of adult patients with relapsed or refractory AML with a NPM1 mutation –...
04.04.25 - 01:18
 35-YEAR INDUSTRY-ACADEMIC PARTNERSHIP YIELDING GROUNDBREAKING ADVANCES FOR SCIENCE AND PATIENTS RENEWS FOR ANOTHER THREE YEARS BETWEEN LA JOLLA INSTITUTE FOR IMMUNOLOGY AND KYOWA KIRIN (PR Newswire)
 
-Agreement extends one of the world's most enduring alliances for drug discovery- -Landmark discoveries from partnership have led to novel drug candidates, including an immunotherapy for moderate to severe atopic dermatitis currently in Phase III clinical trials- - New focus on cell and......
08.03.25 - 14:06
 Amgen Announces Positive Results From Phase 3 Study Of Rocatinlimab In Atopic Dermatitis (AFX)
 
THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) and Kyowa Kirin Co., Ltd. announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an investigational T-cell reb......
08.03.25 - 12:03
 AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PR Newswire)
 
Ongoing Studies are Evaluating Long-Term Maintenance and Durability THOUSAND OAKS, Calif. and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today announced new results from the ongoing ROCKET Phase 3 clinical trial program......
06.02.25 - 22:54
 Kyowa Kirin GAAP EPS of ¥113.06, revenue of ¥495.56B (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
06.02.25 - 19:00
 Kura Oncology Cancer Study Hits Primary Goal, Lays Out Plans For Phase 3 Studies (Benzinga)
 
Kura Oncology and Kyowa Kirin reported positive Phase 2 results for ziftomenib in AML and plan Phase 3 trials, with an NDA submission set for Q2 2025. read more...
05.02.25 - 22:03
 Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs (GlobeNewswire EN)
 
– KOMET-001 registrational trial in R/R NPM1-m AML achieved primary CR/CRh endpoint; topline data submitted for presentation at an upcoming medical meeting –...
26.12.24 - 21:30
 XFRA : DIVIDEND/INTEREST INFORMATION - 27.12.2024 - JP3256000005 (XETRA)
 
Das Instrument KY4 JP3256000005 KYOWA KIRIN CO. LTD. EQUITY wird ex Dividende/Zinsen gehandelt am 27.12.2024 The instrument KY4 JP3256000005 KYOWA KIRIN CO. LTD. EQUITY has its ex-dividend/interest day on 27.12.2024...
24.12.24 - 06:09
 XFRA : DIVIDEND/INTEREST INFORMATION - 27.12.2024 - JP3256000005 (XETRA)
 
Das Instrument KY4 JP3256000005 KYOWA KIRIN CO. LTD. EQUITY wird cum Dividende/Zinsen gehandelt am 24.12.2024 und ex Dividende/Zinsen am 27.12.2024 The instrument KY4 JP3256000005 KYOWA KIRIN CO. LTD. EQUITY has its pre-dividend/interest day on 24.12.2024 and its ex-dividend/interest day on 27.12.2024...
21.11.24 - 00:27
 Kura stock slides 17% on Kyowa Kirin deal for ziftomenib (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
20.11.24 - 23:03
 Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias (GlobeNewswire EN)
 
– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in near-term milestone payments and opt-in right for solid tumors –...
31.10.24 - 12:39
 Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company (PR Newswire)
 
Masashi Miyamoto to be named Chairman and CEO Abdul Mullick to be named President and COO Changes designed to further deliver on company's 2030 Vision and commitment to advancing novel treatments for Bone/Mineral, Intractable Hematological Diseases/Hemato-Oncology and Rare Diseases TOKYO,......
02.08.24 - 17:09
 Kyowa Kirin Non-GAAP EPS of ¥70.75, revenue of ¥232.9B (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
26.06.24 - 23:39
 XFRA : DIVIDEND/INTEREST INFORMATION - 27.06.2024 - JP3256000005 (XETRA)
 
Das Instrument KY4 JP3256000005 KYOWA KIRIN CO. LTD. EQUITY wird ex Dividende/Zinsen gehandelt am 27.06.2024 The instrument KY4 JP3256000005 KYOWA KIRIN CO. LTD. EQUITY has its ex-dividend/interest day on 27.06.2024...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Ich brauche keine Lobhudeleien. Ich habe schon zwei so genannte Jubiläumssendungen mit so viel Verlogenheit erlebt, daß ich keine dritte mehr möchte. - Karl Moik
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!